IS5415A - Gataðar öreiningar og aðferðir til notkunar þeirra - Google Patents

Gataðar öreiningar og aðferðir til notkunar þeirra

Info

Publication number
IS5415A
IS5415A IS5415A IS5415A IS5415A IS 5415 A IS5415 A IS 5415A IS 5415 A IS5415 A IS 5415A IS 5415 A IS5415 A IS 5415A IS 5415 A IS5415 A IS 5415A
Authority
IS
Iceland
Prior art keywords
dispersions
perforated
patient
suspension medium
cleansers
Prior art date
Application number
IS5415A
Other languages
English (en)
Other versions
IS2154B (is
Inventor
E. Tarara Thomas
Weers Jeffry
Kabalnov Alexey
G. Schutt Enest
Dellamary Luis
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27369827&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS5415(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of IS5415A publication Critical patent/IS5415A/is
Publication of IS2154B publication Critical patent/IS2154B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/926—Topical chemical, e.g. cosmetic or sunscreen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Nanotechnology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Optics & Photonics (AREA)
IS5415A 1997-09-29 2000-03-24 Gataðar öreiningar og aðferðir til notkunar þeirra IS2154B (is)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6033797P 1997-09-29 1997-09-29
US10693298A 1998-06-29 1998-06-29
US13384898A 1998-08-14 1998-08-14
PCT/US1998/020602 WO1999016419A1 (en) 1997-09-29 1998-09-29 Perforated microparticles and methods of use

Publications (2)

Publication Number Publication Date
IS5415A true IS5415A (is) 2000-03-24
IS2154B IS2154B (is) 2006-10-13

Family

ID=27369827

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5415A IS2154B (is) 1997-09-29 2000-03-24 Gataðar öreiningar og aðferðir til notkunar þeirra

Country Status (28)

Country Link
EP (4) EP1019022B2 (is)
JP (9) JP5372306B2 (is)
KR (4) KR100572171B1 (is)
CN (1) CN1169520C (is)
AT (3) ATE239447T1 (is)
AU (4) AU757337C (is)
BG (1) BG64816B1 (is)
BR (1) BR9812693A (is)
CA (4) CA2304975C (is)
CZ (1) CZ300758B6 (is)
DE (2) DE69814428T2 (is)
DK (2) DK1019021T4 (is)
EA (2) EA003665B1 (is)
EE (1) EE04628B1 (is)
ES (3) ES2195415T3 (is)
HK (1) HK1031680A1 (is)
HR (1) HRP20000175B1 (is)
IL (2) IL135126A0 (is)
IS (1) IS2154B (is)
ME (1) MEP4108A (is)
NO (1) NO340149B1 (is)
NZ (1) NZ503464A (is)
PL (1) PL195212B1 (is)
PT (1) PT1019022E (is)
RS (1) RS50182B (is)
SK (1) SK285068B6 (is)
TR (1) TR200000819T2 (is)
WO (3) WO1999016422A1 (is)

Families Citing this family (235)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US6503480B1 (en) 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
SK285068B6 (sk) * 1997-09-29 2006-05-04 Nektar Therapeutics Práškový prostriedok, mikrosféry, spôsob tvorby časticového prostriedku obsahujúceho perforované mikroštruktúry prostredníctvom sušenia striekaním a spôsob tvorby prášku obsahujúceho perforované mikroštruktúry prostredníctvom sušenia striekaním
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
GB9727102D0 (en) * 1997-12-22 1998-02-25 Andaris Ltd Microparticles and their therapeutic use
KR100796220B1 (ko) * 1998-06-29 2008-01-21 넥타르 테라퓨틱스 미립자 전달 시스템 및 사용 방법
WO2000000215A1 (en) * 1998-06-29 2000-01-06 Inhale Therapeutic Systems, Inc. Particulate delivery systems and methods of use
US6630169B1 (en) 1999-03-31 2003-10-07 Nektar Therapeutics Particulate delivery systems and methods of use
US6223455B1 (en) † 1999-05-03 2001-05-01 Acusphere, Inc. Spray drying apparatus and methods of use
BR0010984A (pt) * 1999-05-27 2002-04-30 Acusphere Inc Matrizes porosas de medicamento e processos para fabricação das mesmas
ATE555773T1 (de) 1999-06-09 2012-05-15 Sievers Robert E Überkritische fluidgestützte verneblung und blasen trochnen
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
AU763041B2 (en) * 1999-08-25 2003-07-10 Alkermes, Inc. Modulation of release from dry powder formulations
AU2729101A (en) 1999-12-21 2001-07-03 Rxkinetix, Inc. Particulate drug-containing products and method of manufacture
US6761909B1 (en) 1999-12-21 2004-07-13 Rxkinetix, Inc. Particulate insulin-containing products and method of manufacture
JP2003522304A (ja) 2000-02-08 2003-07-22 スリーエム イノベイティブ プロパティズ カンパニー インク定着材料およびインク定着方法
GB0003935D0 (en) * 2000-02-08 2000-04-12 King S College London Formulation for dry powder inhaler
ATE304453T1 (de) 2000-02-08 2005-09-15 3M Innovative Properties Co Verbesserte verfahren für kalten bildtransfer
TWI290473B (en) 2000-05-10 2007-12-01 Alliance Pharma Phospholipid-based powders for drug delivery
US8404217B2 (en) * 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
WO2001087277A2 (en) * 2000-05-15 2001-11-22 Vectura Limited Method of manufacturing particles
NZ523693A (en) * 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
US7141236B2 (en) 2000-07-28 2006-11-28 Nektar Therapeutics Methods and compositions for delivering macromolecules to or via the respiratory tract
DE10064219B9 (de) * 2000-12-22 2009-02-12 Nasalis Pain Relief International Gmbh Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung
US20030072717A1 (en) 2001-02-23 2003-04-17 Vapotronics, Inc. Inhalation device having an optimized air flow path
GB0106403D0 (en) * 2001-03-15 2001-05-02 Pharmaceutical Profiles Labelling of dry powder formulations for inhalation
GB0107106D0 (en) * 2001-03-21 2001-05-09 Boehringer Ingelheim Pharma Powder inhaler formulations
JP2004528339A (ja) * 2001-04-26 2004-09-16 ネクター セラピューティクス 気道に対して又は気道を介して高分子を送達するための新規方法及び組成物
US7905230B2 (en) 2001-05-09 2011-03-15 Novartis Ag Metered dose inhaler with lockout
CA2448022C (en) * 2001-05-21 2013-11-12 Injet Digital Aerosols Limited Compositions for protein delivery via the pulmonary route
JP2005503425A (ja) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
WO2002094218A2 (en) 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US6759029B2 (en) 2001-05-24 2004-07-06 Alexza Molecular Delivery Corporation Delivery of rizatriptan and zolmitriptan through an inhalation route
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
JP2004531333A (ja) 2001-06-20 2004-10-14 ネクター セラピューティクス 粉末エアロゾル化装置及び方法
US8337816B2 (en) * 2001-09-17 2012-12-25 Glaxo Group Limited Dry powder medicament formulations
CA2464656C (en) 2001-11-01 2013-07-16 Nektar Therapeutics Spray drying methods and compositions thereof
WO2003041693A1 (en) 2001-11-09 2003-05-22 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
EP1446102A1 (en) 2001-11-21 2004-08-18 Alexza Molecular Delivery Corporation Delivery of caffeine through an inhalation route
MXPA04005865A (es) 2001-12-19 2004-09-13 Nektar Therapeutics Suministro de aminoglucosidos a los pulmones.
EP1458630A1 (en) 2001-12-21 2004-09-22 Nektar Therapeutics Capsule package with moisture barrier
CN1642533A (zh) * 2002-03-18 2005-07-20 山之内制药株式会社 吸入用粉末医药组合物及其制备方法
US7008644B2 (en) 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
US6941980B2 (en) 2002-06-27 2005-09-13 Nektar Therapeutics Apparatus and method for filling a receptacle with powder
MY142204A (en) 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
CN1694689A (zh) * 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
US7516741B2 (en) 2002-12-06 2009-04-14 Novartis Ag Aerosolization apparatus with feedback mechanism
CA2509216A1 (en) * 2002-12-13 2004-07-01 Adagit Pharmaceutical porous particles
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP1589947B2 (en) * 2002-12-31 2019-01-30 Novartis AG Pharmaceutical formulation with an insoluble active agent for pulmonary administration
US7669596B2 (en) 2002-12-31 2010-03-02 Novartis Pharma Ag Aerosolization apparatus with rotating capsule
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
EP1598074B1 (en) * 2003-02-28 2019-01-02 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
CN1758930B (zh) 2003-03-27 2010-06-09 株式会社新日本科学 鼻腔用粉末药剂喷药装置
DK1610850T3 (da) 2003-04-09 2012-06-25 Novartis Ag Aerosolapparat med luftindløbsskærm
US8869794B1 (en) 2003-04-09 2014-10-28 Novartis Pharma Ag Aerosolization apparatus with capsule puncturing member
PL1615689T3 (pl) 2003-04-09 2016-06-30 Novartis Ag Urządzenie do aerozolizacji z prowadnicą wyrównującą do przebijania kapsułki
WO2004104493A2 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same
WO2005000267A2 (en) 2003-05-28 2005-01-06 Nektar Therapeutics Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agentmicroparticle with a partial or complete amino acid and/or phospholipid coat
JP2007533634A (ja) * 2003-09-30 2007-11-22 アキュスフィア， インコーポレイテッド 注射、経口、または局所用の徐放性医薬製剤
US7621299B2 (en) 2003-10-03 2009-11-24 Cabot Corporation Method and apparatus for filling a vessel with particulate matter
EP1677738A2 (en) * 2003-10-31 2006-07-12 Point Biomedical Corporation Reconstitutable microsphere compositions useful as ultrasonic contrast agents
EP1701714A2 (en) 2004-01-07 2006-09-20 Nektar Therapeutics Improved sustained release compositions for pulmonary administration of insulin
US20080026066A1 (en) * 2004-04-13 2008-01-31 Cambridge Biostability Limited Liquids Containing Suspended Glass Particles
ITMI20040795A1 (it) 2004-04-23 2004-07-23 Eratech S R L Composizione farmaceutica solida secca suo processo di preparazione e sospensione acquosa stabile ottenuta dalla stessa
US8012457B2 (en) 2004-06-04 2011-09-06 Acusphere, Inc. Ultrasound contrast agent dosage formulation
CA2567785A1 (en) 2004-06-21 2006-01-05 Nektar Therapeutics Composition comprising amphotericin b methods and systems
US8513204B2 (en) 2004-06-21 2013-08-20 Novartis Ag Compositions comprising amphotericin B, mehods and systems
JP4922762B2 (ja) 2004-08-10 2012-04-25 株式会社新日本科学 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
EP2431026A1 (en) 2004-08-13 2012-03-21 Boehringer Ingelheim International GmbH Extended release pellet formulation containing Pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
BRPI0513846A (pt) 2004-08-13 2008-05-20 Boehringer Ingelheim Int formulação de comprimido de liberação prolongada contendo pramipexol ou um sal farmaceuticamente aceitável do mesmo, método para a fabricação do mesmo e o uso do mesmo
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
MX2007011772A (es) 2005-03-23 2007-12-05 Elan Pharma Int Ltd Formulaciones de antihistaminico y corticosteroide de materia en nanoparticulas.
JO3058B1 (ar) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
WO2006124446A2 (en) * 2005-05-12 2006-11-23 Nektar Therapeutics Sustained release microparticles for pulmonary delivery
AU2006287934B2 (en) 2005-05-18 2012-12-13 Nektar Therapeutics Valves, devices, and methods for endobronchial therapy
TW200716174A (en) 2005-05-19 2007-05-01 Centocor Inc Anti-MCP-1 antibodies, compositions, methods and uses
HUE042561T2 (hu) 2005-06-30 2019-07-29 Janssen Biotech Inc Anti-IL-23-ellenanyagok, készítmények, eljárások és alkalmazások
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
JP5113328B2 (ja) * 2005-11-07 2013-01-09 田辺三菱製薬株式会社 エマルション並びにそれを用いた目的物質粒子の製造方法及び医薬品
US8293869B2 (en) 2005-12-16 2012-10-23 Nektar Therapeutics Polymer conjugates of GLP-1
RS53685B1 (en) 2005-12-29 2015-04-30 Janssen Biotech Inc. HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, METHODS AND APPLICATIONS
WO2007086039A1 (en) * 2006-01-27 2007-08-02 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin A method of producing porous microparticles
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
CN102274557B (zh) 2006-08-09 2014-12-03 精达制药公司 渗透性递送***和活塞组件
CN101668544B (zh) 2006-12-26 2013-04-24 株式会社新日本科学 经鼻投用制剂
US20080216828A1 (en) 2007-03-09 2008-09-11 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
WO2008133908A2 (en) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
WO2009023803A2 (en) * 2007-08-15 2009-02-19 Abbott Respiratory Llc Modulated release formulation for the delivery of one or more medicaments
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
WO2009120619A2 (en) * 2008-03-24 2009-10-01 Novartis Ag Nuclease compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions
PL220269B1 (pl) 2008-04-21 2015-09-30 Przedsiębiorstwo Produkcji Farmaceutycznej Hasco Lek Spółka Akcyjna Kompozytowy nośnik leków proszkowych, sposób wytwarzania nośnika leków oraz urządzenie do wytwarzania cząstek nośnika kompozytowego
BRPI0913021A2 (pt) 2008-05-15 2015-10-13 Novartis Ag distribuição pulmonar de uma fluoroquinolona
CA2737040C (en) 2008-09-19 2017-05-02 Nektar Therapeutics Polymer conjugates of therapeutic peptides
DK2356269T3 (en) 2008-10-31 2016-08-15 Janssen Biotech Inc FIBRONECTIN TYPE III DOMAIN-BASED SCAFFOLD COMPOSITIONS, PROCEDURES AND APPLICATIONS
AU2009312598A1 (en) * 2008-11-04 2010-05-14 Cipla Limited Pharmaceutical aerosol composition
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
DK2396011T3 (en) 2009-02-12 2016-04-25 Janssen Biotech Inc Fibronectin TYPE III DOMAIN-BASED SCAFFOLD COMPOSITIONS, METHODS AND USES
EP2221048A1 (en) 2009-02-18 2010-08-25 Siegfried Generics International AG Pharmaceutical composition for inhalation
US8974828B2 (en) 2009-03-18 2015-03-10 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
PT2410981T (pt) 2009-03-26 2017-05-25 Pulmatrix Inc Formulações em pó seco e métodos para tratar doenças pulmonares
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
KR20100123240A (ko) * 2009-05-15 2010-11-24 포항공과대학교 산학협력단 호흡기 염증성 질환의 치료 또는 예방을 위한 호흡기내 투여용 약학 제제 및 상기 질환의 치료 또는 예방 방법
EP2429495A4 (en) 2009-05-15 2014-01-22 Shin Nippon Biomedical Lab Ltd INTRANASAL PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PHARMACOKINETICS
CN107669664B (zh) * 2009-05-29 2020-07-10 珍珠治疗公司 经呼吸递送活性剂的组合物及相关方法和***
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
GB2472327B (en) 2009-07-31 2013-03-13 Shin Nippon Biomedical Lab Ltd Intranasal granisetron and nasal applicator
AU2010298733B2 (en) 2009-09-28 2014-10-09 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
CN102811715A (zh) * 2009-12-08 2012-12-05 悉尼大学 可吸入制剂
WO2012030647A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
US9061352B2 (en) 2010-08-30 2015-06-23 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
IL286573B (en) 2010-09-29 2022-08-01 Pulmatrix Operating Co Inc Monovalent metallic cation dry powders for inhalation
WO2012050945A1 (en) 2010-09-29 2012-04-19 Pulmatrix, Inc. Cationic dry powders
CN103228266B (zh) 2010-10-29 2017-11-14 健康科学西部大学 三元混合物制剂
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CA2827990A1 (en) * 2011-02-25 2012-08-30 The Johns Hopkins University Chalcone derivatives as nrf2 activators
GB201108039D0 (en) * 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
WO2012158166A1 (en) * 2011-05-17 2012-11-22 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of two or more active agents
GB201117619D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117621D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
EP2601941A1 (en) 2011-12-06 2013-06-12 Ludwig-Maximilians-Universität München Beta-O/S/N fatty acid based compounds as antibacterial and antiprotozoal agents
AU2013246926B2 (en) 2012-04-13 2016-07-21 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
ES2749096T3 (es) 2012-10-25 2020-03-19 Massachusetts Gen Hospital Terapias de combinación para el tratamiento de la enfermedad de Alzheimery transtornos relacionados
KR102275109B1 (ko) 2013-03-15 2021-07-07 펄 테라퓨틱스 인코포레이티드 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
US10149823B2 (en) 2013-04-30 2018-12-11 Otitopic Inc. Dry powder formulations and methods of use
KR101543507B1 (ko) * 2013-05-15 2015-08-11 씨제이헬스케어 주식회사 연속 공정의 미립구의 제조 방법 및 이로부터 제조된 미립구
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
US9861608B2 (en) * 2013-05-23 2018-01-09 Aztherapies, Inc Methods for delivering cromolyn
WO2014207213A1 (en) 2013-06-28 2014-12-31 Medizinische Universität Innsbruck Novel inhibitors of protein kinase c epsilon signaling
CN110305095A (zh) 2013-10-22 2019-10-08 综合医院公司 色甘酸衍生物以及成像和治疗的相关方法
CN106456595A (zh) 2014-02-10 2017-02-22 帕塔拉制药有限责任公司 用于***性病症的肥大细胞稳定剂治疗
DK3104854T3 (da) 2014-02-10 2020-05-04 Respivant Sciences Gmbh Mast-celle-stabilisatorer til lungesygdomsbehandling
DK3107548T3 (da) 2014-02-20 2022-07-18 Otitopic Inc Tørpulverformuleringer til inhalation
EP2947460A1 (en) 2014-05-22 2015-11-25 Medizinische Universität Wien Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists
EP3179986B1 (en) 2014-07-31 2023-03-15 Vectura Inc. Dry powder formulations for inhalation
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
DK3212212T3 (da) 2014-10-31 2020-12-21 Univ Monash Pulverformulering
JP6395216B2 (ja) * 2014-11-13 2018-09-26 国立大学法人大阪大学 液体に含まれる超微細バブルの測定方法及びその測定装置
WO2016118625A1 (en) 2015-01-20 2016-07-28 Incarda Therapeutics, Inc. Unit aerosol doses for anticoagulation
WO2016135140A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135138A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135139A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135137A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
US10864190B2 (en) 2015-04-22 2020-12-15 CeMM—FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH Combination of an antiandrogen with a vitamin K antagonist or with a gamma-glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
CA2987766A1 (en) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Implant placement and removal systems
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
EP3556347B1 (en) 2015-12-04 2021-03-24 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
US10723748B2 (en) 2015-12-09 2020-07-28 Medizinische Universität Wien Monomaleimide-functionalized platinum compounds for cancer therapy
EP3402788A1 (en) 2016-01-15 2018-11-21 Universität Hamburg Flavonoide-type compounds bearing an o-rhamnosyl residue
CA3012333A1 (en) 2016-02-01 2017-08-10 Incarda Therapeutics, Inc. Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
AU2017220611A1 (en) 2016-02-15 2018-08-30 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh TAF1 inhibitors for the therapy of cancer
KR20180128471A (ko) 2016-03-29 2018-12-03 얀센 바이오테크 인코포레이티드 항-il12 및/또는 항-il23 항체의 증가된 투여 간격을 사용한 건선의 치료
WO2017178820A1 (en) 2016-04-15 2017-10-19 Oxford University Innovation Limited Adenosine receptor modulators for the treatment of circadian rhythm disorders
SG10201913699QA (en) 2016-05-16 2020-03-30 Intarcia Therapeutics Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
MX2019000641A (es) 2016-07-15 2019-06-10 Poseida Therapeutics Inc Composiciones de mucina1-receptor de antigeno quimerico y metodos para su uso.
JP2019524721A (ja) 2016-07-15 2019-09-05 ポセイダ セラピューティクス， インコーポレイテッド キメラ抗原受容体および使用方法
AU2017321495A1 (en) 2016-08-31 2019-03-21 Respivant Sciences Gmbh Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
US20190240194A1 (en) 2016-08-31 2019-08-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
IL265349B2 (en) 2016-09-19 2023-03-01 Mexichem Fluor Sa De Cv Pharmaceutical composition
BR112019005168A2 (pt) 2016-09-19 2019-06-11 Mexichem Fluor Sa De Cv composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente que sofre ou susceptível de sofrer de um distúrbio respiratório, para melhoria da estabilidade de uma composição farmacêutica e do desempenho de aerossolização de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica
ES2968453T3 (es) 2016-09-19 2024-05-09 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende glicopirrolato
EP3909582B1 (en) 2016-09-19 2023-05-24 Mexichem Fluor S.A. de C.V. Pharmaceutical composition comprising indacaterol
KR20190059305A (ko) 2016-09-30 2019-05-30 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 건선을 치료하는 안전하고 효과적인 방법
JP2019531308A (ja) 2016-10-07 2019-10-31 レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングＲｅｓｐｉｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ 肺線維症の治療のためのクロモリン組成物
EP3538100A2 (en) 2016-11-14 2019-09-18 CeMM - Forschungszentrum für Molekulare Medizin GmbH Combination of a brd4 inhibitor and an antifolate for the therapy of cancer
MX2019005661A (es) 2016-11-16 2019-10-07 Janssen Biotech Inc Método para tratar la psoriasis con el anticuerpo específico anti-il23.
US10835580B2 (en) 2017-01-03 2020-11-17 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
JP2020519628A (ja) 2017-05-10 2020-07-02 インカーダ セラピューティクス， インコーポレイテッド 肺投与によって心臓の状態を処置するための単位用量、エアロゾル、キットおよび方法
EP3634464A4 (en) 2017-05-22 2021-04-07 Insmed Incorporated GLYCOPEPTIDE DERIVATIVE COMPOUNDS AND USES THEREOF
JP7202376B2 (ja) 2017-07-20 2023-01-11 エーゼットセラピーズ， インコーポレイテッド クロモリンナトリウムおよびイブプロフェンの粉末製剤
JP2020532987A (ja) 2017-09-08 2020-11-19 ポセイダ セラピューティクス，インコーポレイティド キメラリガンド受容体（ｃｌｒ）介在性の条件遺伝子発現のための組成物および方法
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
US20210179591A1 (en) 2017-12-05 2021-06-17 Eth Zurich New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors
EP3728305A1 (en) 2017-12-20 2020-10-28 Poseida Therapeutics, Inc. Vcar compositions and methods for use
KR20200129125A (ko) 2018-03-05 2020-11-17 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 크론병을 치료하는 방법
MX2020009309A (es) 2018-03-07 2021-01-08 Poseida Therapeutics Inc Composiciones de cartirina y métodos para su uso.
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
WO2019193159A1 (en) 2018-04-06 2019-10-10 Universität Wien Bumetanide derivatives for the therapy of hyperhidrosis
WO2019193161A1 (en) 2018-04-06 2019-10-10 Universität Wien Bumetanide derivatives for the therapy of stroke and other neurological diseases/disorders involving nkccs
JP2021523138A (ja) 2018-05-11 2021-09-02 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ−２３抗体を使用してうつを治療する方法
US10414721B1 (en) 2018-06-04 2019-09-17 University Of Bern Inhibitor of endocannabinoid cellular reuptake
CA3105392A1 (en) 2018-07-02 2020-01-09 The General Hospital Corporation Powdered formulations of cromolyn sodium and .alpha.-lactose
US20200025776A1 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody
BR112021005467A2 (pt) 2018-09-24 2021-06-22 Janssen Biotech, Inc. método seguro e eficaz para tratar colite ulcerativa com anticorpo anti-il12/il23
AU2019383017A1 (en) 2018-11-20 2021-06-03 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
US20230067929A1 (en) 2018-12-17 2023-03-02 Tolremo Therapeutics Ag Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
EP3897722A4 (en) 2018-12-18 2022-09-14 Janssen Biotech, Inc. SAFE AND EFFECTIVE METHOD OF TREATING LUPUS WITH AN ANTI-IL12/IL23 ANTIBODY
US11390571B2 (en) 2019-01-03 2022-07-19 Aqua Yield Operations LLC PAMAM dendrimers for fertilizer delivery
WO2020183418A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions
EA202192459A1 (ru) 2019-03-18 2021-11-25 Янссен Байотек, Инк. Способ лечения псориаза антителом к il12/il23 у субъектов детского возраста
US11932585B2 (en) 2019-04-12 2024-03-19 Aqua Yield Operations LLC Blended nanoparticle fertilizer delivery
CN110051868A (zh) * 2019-04-15 2019-07-26 宝盈联华(厦门)生物科技有限公司 一种带有硅碳岩、礌石粉的橱柜灭菌器
JP7404671B2 (ja) * 2019-06-25 2023-12-26 株式会社リコー 多孔質微粒子及びその製造方法、並びに医薬組成物
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
WO2021064141A1 (en) 2019-10-02 2021-04-08 Tolremo Therapeutics Ag Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b
WO2021064142A1 (en) 2019-10-02 2021-04-08 Tolremo Therapeutics Ag Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
AU2020366135A1 (en) 2019-10-16 2022-06-02 Proxygen Gmbh Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof
WO2021074418A1 (en) 2019-10-16 2021-04-22 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof
IL297025A (en) 2020-04-14 2022-12-01 Poseida Therapeutics Inc Preparations and methods for use in cancer treatment
WO2021216547A1 (en) 2020-04-20 2021-10-28 Sorrento Therapeutics, Inc. Pulmonary administration of ace2 polypeptides
WO2021214588A1 (en) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Anti-tnf alpha agent for treating coronavirus infections
WO2021214587A1 (en) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Anti-tnf alpha agent for treating viral infections
US20230226057A1 (en) 2020-06-25 2023-07-20 Tolremo Therapeutics Ag Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease
EP3939578A1 (en) 2020-07-13 2022-01-19 Novaremed Ltd. Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease
CN111700883B (zh) * 2020-07-23 2021-04-06 深圳大佛药业股份有限公司 一种硫酸沙丁胺醇缓释型吸入制剂及其生产工艺
US20230270669A1 (en) 2020-09-04 2023-08-31 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
EP3964497A1 (en) 2020-09-04 2022-03-09 Friedrich-Alexander-Universität Erlangen-Nürnberg Substituted vicinal diamine compounds and their use in the treatment, amelioration or prevention of pain
WO2022079290A2 (en) 2020-10-16 2022-04-21 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Cullin ring ubiquitin ligase compounds and uses thereof
CN112495316B (zh) * 2020-10-20 2021-11-19 大连理工大学 一种基于亚稳态乳液制备微纳米凝胶微球的方法
CN116546980A (zh) * 2020-12-11 2023-08-04 江苏恒瑞医药股份有限公司 用于肺部递送的药物组合物
EP4305062A1 (en) 2021-03-12 2024-01-17 Janssen Biotech, Inc. Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
EP4304582A1 (en) 2021-03-12 2024-01-17 Alvarius Pharmaceuticals Ltd. Compositions and methods for treating addictions comprising 5-meo-dmt
US20220298236A1 (en) 2021-03-12 2022-09-22 Janssen Biotech, Inc. Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
TW202304882A (zh) 2021-04-07 2023-02-01 瑞士商妥瑞莫醫療公司 雜環衍生物、醫藥組成物及彼等於治療或改善癌症之用途
EP4367138A1 (en) 2021-07-09 2024-05-15 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions
CA3236779A1 (en) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
CN118251413A (zh) 2021-11-15 2024-06-25 詹森生物科技公司 用抗il23特异性抗体治疗克罗恩病的方法
KR20240103043A (ko) 2021-11-23 2024-07-03 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 궤양성 결장염을 치료하는 방법
WO2023187707A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of treating mild to moderate psoriasis with il-23 specific antibody
WO2023203172A1 (en) 2022-04-20 2023-10-26 Proxygen Gmbh Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
WO2023223265A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for evaluating and treating psoriatic arthritis with il23 antibody
CN115144310B (zh) * 2022-07-01 2024-07-19 重庆交通大学 一种旋桨式絮凝沉降试验装置及方法
WO2024110898A1 (en) 2022-11-22 2024-05-30 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1410588A (en) † 1971-08-10 1975-10-22 Fisons Ltd Composition
JPS5134879A (en) * 1974-09-19 1976-03-24 Eisai Co Ltd Bishochukuryushinoseizoho
US4147766A (en) † 1976-06-09 1979-04-03 Armour Pharmaceutical Company Macrospherical particles of anti-perspirants
DE3268533D1 (en) † 1981-07-24 1986-02-27 Fisons Plc Inhalation drugs, methods for their production and pharmaceutical formulations containing them
EP0391893B1 (en) * 1983-11-14 1993-08-25 The University of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
GB8502892D0 (en) * 1985-02-05 1985-03-06 Sterwin Ag Aerosol composition
EP0223831B1 (en) * 1985-05-22 1992-07-15 Liposome Technology, Inc. Liposome inhalation method and system
US4950477A (en) † 1988-08-23 1990-08-21 Memorial Hospital For Cancer And Allied Dieseas Method of preventing and treating pulmonary infection by fungi using aerosolized polyenes
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
EP0432232B1 (en) * 1989-05-01 1994-01-05 Alkermes Controlled Therapeutics, Inc. Process for producing small particles of biologically active molecules
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
JPH05507090A (ja) * 1990-05-08 1993-10-14 リポサーム　テクノロジー　インコーポレイテッド 直接噴霧乾燥された薬剤／脂質粉末組成物
US5126123A (en) † 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations
US5230884A (en) † 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5304125A (en) † 1990-10-05 1994-04-19 The University Of North Carolina Apparatus for administering solid particulate aerosols to the lungs
US5616311A (en) * 1991-01-15 1997-04-01 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
EP0495187B1 (en) * 1991-01-15 1997-01-22 Hemosphere, Inc. Protein nanomatrixes and method of production
US5182097A (en) † 1991-02-14 1993-01-26 Virginia Commonwealth University Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
CA2082951C (en) † 1991-03-15 1999-12-21 Robert M. Platz Pulmonary administration of granulocyte colony stimulating factor
SE9101090D0 (sv) * 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
JPH05500229A (ja) * 1991-04-12 1993-01-21 東レ株式会社 固体ポリペプチド微粒子のエアロゾル製剤とその製造方法
CZ271493A3 (en) * 1991-06-10 1994-07-13 Schering Corp Aerosol preparations without chlorofluorinated hydrocarbons
ATE260641T1 (de) * 1991-12-18 2004-03-15 Minnesota Mining & Mfg Aerosolzusammensetzungen für arzneimittelsuspensionen
US5376359A (en) † 1992-07-07 1994-12-27 Glaxo, Inc. Method of stabilizing aerosol formulations
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5354934A (en) † 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
DE4323636A1 (de) * 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
EP1550464A1 (en) * 1993-07-30 2005-07-06 IMCOR Pharmaceutical Co. Stabilized microbubble composition for ultrasound
US5798091A (en) † 1993-07-30 1998-08-25 Alliance Pharmaceutical Corp. Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
EP0655237A1 (de) * 1993-11-27 1995-05-31 Hoechst Aktiengesellschaft Medizinische Aerosolformulierung
US5540909A (en) * 1994-09-28 1996-07-30 Alliance Pharmaceutical Corp. Harmonic ultrasound imaging with microbubbles
AU701440B2 (en) * 1994-09-29 1999-01-28 Quadrant Drug Delivery Limited Spray-dried microparticles as therapeutic vehicles
GB9423419D0 (en) * 1994-11-19 1995-01-11 Andaris Ltd Preparation of hollow microcapsules
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
EE9700138A (et) * 1994-12-22 1997-12-15 Astra Aktiebolag Aerosoolravimvormid
JP3708553B2 (ja) * 1995-04-14 2005-10-19 ネクター セラピューティクス 向上した分散性を有する粉末型薬理組成物
ATE265863T1 (de) † 1995-06-07 2004-05-15 Imarx Pharmaceutical Corp Neue zielgerichtete mittel zur diagnostischen und therapeutischen verwendung
US5654007A (en) * 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US6041777A (en) * 1995-12-01 2000-03-28 Alliance Pharmaceutical Corp. Methods and apparatus for closed-circuit ventilation therapy
GB9606677D0 (en) * 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
CA2277801C (en) † 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
SK285068B6 (sk) * 1997-09-29 2006-05-04 Nektar Therapeutics Práškový prostriedok, mikrosféry, spôsob tvorby časticového prostriedku obsahujúceho perforované mikroštruktúry prostredníctvom sušenia striekaním a spôsob tvorby prášku obsahujúceho perforované mikroštruktúry prostredníctvom sušenia striekaním

Also Published As

Publication number Publication date
RS50182B (sr) 2009-05-06
HRP20000175B1 (en) 2004-06-30
JP2001517691A (ja) 2001-10-09
EA200200036A1 (ru) 2002-04-25
DE69813853T2 (de) 2004-01-29
DK1019021T3 (da) 2003-11-10
SK4492000A3 (en) 2000-09-12
KR20010030801A (ko) 2001-04-16
CA2304820C (en) 2009-06-23
CA2304819A1 (en) 1999-04-08
KR20010030788A (ko) 2001-04-16
JP2013216688A (ja) 2013-10-24
EP1019020A1 (en) 2000-07-19
SK285068B6 (sk) 2006-05-04
NO20001618D0 (no) 2000-03-28
KR100572171B1 (ko) 2006-04-19
DK1019022T3 (da) 2003-07-28
YU18300A (sh) 2003-02-28
JP4526702B2 (ja) 2010-08-18
EA003665B1 (ru) 2003-08-28
NO340149B1 (no) 2017-03-13
JP2011116788A (ja) 2011-06-16
JP2014169335A (ja) 2014-09-18
AU757153B2 (en) 2003-02-06
JP2003525841A (ja) 2003-09-02
JP2003525842A (ja) 2003-09-02
AU750567B2 (en) 2002-07-25
ES2195415T3 (es) 2003-12-01
EP1019021A1 (en) 2000-07-19
HK1031680A1 (en) 2001-06-22
BR9812693A (pt) 2000-08-22
EP1019023B1 (en) 2003-05-07
IS2154B (is) 2006-10-13
PT1019022E (pt) 2003-08-29
AU756693B2 (en) 2003-01-23
AU757337C (en) 2005-11-03
DK1019022T4 (da) 2010-11-08
IL135126A0 (en) 2001-05-20
CZ20001115A3 (cs) 2000-09-13
PL339732A1 (en) 2001-01-02
AU757337B2 (en) 2003-02-20
EA200000375A1 (ru) 2000-12-25
CZ300758B6 (cs) 2009-08-05
KR20010030810A (ko) 2001-04-16
KR100575070B1 (ko) 2006-05-03
EP1019021B2 (en) 2012-12-26
WO1999016419A9 (en) 1999-08-19
JP6100114B2 (ja) 2017-03-22
AU1185799A (en) 1999-04-23
DE69813853T3 (de) 2011-05-12
NO20001618L (no) 2000-05-19
CA2304975A1 (en) 1999-04-08
EA002562B1 (ru) 2002-06-27
TR200000819T2 (tr) 2001-06-21
ATE248583T1 (de) 2003-09-15
HRP20000175A2 (en) 2001-06-30
EP1019023A1 (en) 2000-07-19
EP1019022B1 (en) 2003-04-23
ATE239447T1 (de) 2003-05-15
DE69814428D1 (de) 2003-06-12
DE69813853D1 (de) 2003-05-28
DK1019021T4 (da) 2013-01-07
ES2205560T5 (es) 2013-04-16
CN1169520C (zh) 2004-10-06
JP5739197B2 (ja) 2015-06-24
CA2304973A1 (en) 1999-04-08
AU1064499A (en) 1999-04-23
WO1999016419A1 (en) 1999-04-08
AU9677298A (en) 1999-04-23
CA2304975C (en) 2009-06-16
JP5372306B2 (ja) 2013-12-18
ES2195408T3 (es) 2003-12-01
DE69814428T2 (de) 2004-05-13
KR100599634B1 (ko) 2006-07-12
ES2205560T3 (es) 2004-05-01
NZ503464A (en) 2002-05-31
WO1999016421A1 (en) 1999-04-08
BG104253A (en) 2000-11-30
JP2010047615A (ja) 2010-03-04
EP1019021B1 (en) 2003-09-03
CA2304819C (en) 2008-04-08
EP1019022B2 (en) 2010-07-28
CN1272058A (zh) 2000-11-01
ES2195408T5 (es) 2010-11-25
CA2304973C (en) 2009-11-17
EE04628B1 (et) 2006-06-15
BG64816B1 (bg) 2006-05-31
IL135126A (en) 2006-04-10
EE200000194A (et) 2001-04-16
KR20010030787A (ko) 2001-04-16
PL195212B1 (pl) 2007-08-31
JP6078498B2 (ja) 2017-02-08
ATE238035T1 (de) 2003-05-15
EP1019022A1 (en) 2000-07-19
WO1999016422A1 (en) 1999-04-08
JP2001517692A (ja) 2001-10-09
KR100589926B1 (ko) 2006-06-15
AU9677098A (en) 1999-04-23
MEP4108A (xx) 2010-02-10
CA2304820A1 (en) 1999-04-08
JP2013199497A (ja) 2013-10-03

Similar Documents

Publication Publication Date Title
IS5415A (is) Gataðar öreiningar og aðferðir til notkunar þeirra
DK0904056T3 (da) Fremgangsmåde og anordning til inhalation af partikelformige lægemidler
ES2116353T3 (es) Polvos para inhalacion y procedimiento para su fabricacion.
PL371736A1 (en) Method for administering glp-1 molecules
DE69816054D1 (de) Einmalinhalator
NO981746L (no) Utlevering av biologisk aktive polypeptider
MXPA02008403A (es) Mejoras en o relacionadas con el suministro de farmacos por via oral.
SE9701956D0 (sv) New composition of matter
MY117918A (en) Use of an h+, k+- atpase inhibitor in the treatment of nasal polyps
ATE271852T1 (de) Verbesserte inhalationspräparate
MXPA04001912A (es) Aminobenzofenonas novedosas.
DE59708495D1 (de) Feste instant-release-darreichungsformen und verfahren zu ihrer herstellung
DE60007074D1 (de) Sulfatierte phosphatidylinositole, ihre herstellung und verwendung
EP1110547A3 (en) Helium and neon as means delivering drug in inhaler
SE9402383D0 (sv) Förfarande och anordning för att införa ett ämne till ett slutet utrymme